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Atherosclerotic plaque rupture is the primary mechanism responsible for myocardial infarction and
stroke, the top two killers worldwide. Despite being potentially fatal, the ubiquitous prevalence of
atherosclerosis amongst the middle aged and elderly renders individual events relatively rare. This
makes the accurate prediction of MI and stroke challenging. Advances in imaging techniques now allow
detailed assessments of plaque morphology and disease activity. Both CT and MR can identify certain
unstable plaque characteristics thought to be associated with an increased risk of rupture and events. PET
imaging allows the activity of distinct pathological processes associated with atherosclerosis to be
measured, differentiating patients with inactive and active disease states. Hybrid integration of PET with
CT or MR now allows for an accurate assessment of not only plaque burden and morphology but plaque
biology too. In this review, we discuss how these advanced imaging techniques hold promise in rede-
fining our understanding of stable and unstable coronary artery disease beyond symptomatic status, and
how they may refine patient risk-prediction and the rationing of expensive novel therapies.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atherosclerotic plaque rupture is the primary mechanism
responsible for two of the biggest killers worldwide: myocardial
infarction and stroke [1]. In 2015, 423 million people were esti-
mated to be living with cardiovascular disease, and it caused an
estimated 18 million deaths. Whilst the clinical effects of athero-
sclerotic plaque rupture can be devastating, the development of
atheromatous plaque is itself a silent and for many a benign pro-
cess. Indeed, atherosclerosis is an almost ubiquitous finding in
older patients the majority of whom will never suffer a cardiovas-
cular event. Perhaps, the major challenge facing contemporary
cardiovascular researchers is therefore to develop methods of ac-
curate risk prediction without over medicalizing the population as
a whole. In this review, we will briefly discuss the pathophysiology
of atherosclerosis before investigating novel non-invasive imaging
methods aimed at detecting unstable atherosclerotic plaque and
measuring disease activity in the coronary arteries and large ves-
sels. These advanced imaging techniques hold promise in redefin-
ing our understanding of stable and unstable coronary arterylar Imaging Institute, Icahn
Pl, New York, NY 10029, USA.
.
B.V. This is an open access article udisease beyond a patient's symptomatic status with the potential to
improve our pathological understanding, to refine patient risk-
prediction and to appropriately target expensive novel therapies.
1.1. Pathophysiology of atherosclerosis
Atherosclerosis is a smouldering immunoinflammatory disease
fuelled by lipids [2]. It is characterised by focal thickening of the
arterial intima (plaque formation) in medium and large sized ar-
teries. Within the plaques lipid, inflammatory infiltrates, smooth
muscle cells and connective tissues are found. An injury to the
plaque cap known as a plaque rupture results in exposure of its core
contents to the blood, causing acute thrombus formation and either
partial or complete occlusion of the vessel lumen [3]. Athero-
thrombosis from plaque rupture is the most common cause of fatal
myocardial infarction, accounting for approximately three quarters
of cases, with plaque erosion accounting for the remaining quarter
[4]. However, the majority of coronary plaque rupture events
appear to be clinically silent, resulting in plaque growth rather than
myocardial infarction.
Atherosclerosis begins in a hypercholesterolaemic state where
low-density lipoproteins (LDL) infiltrate the endothelial wall. Sub-
sequent oxidation of LDL molecules causes an inflammatory
response with infiltration of T-lymphocytes and macrophages that
consume LDL and form foam cells. This is initially protective, butnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Schematic representation of morphological and biological targets for unstable
plaque imaging.
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triggered, contributing to further inflammation and the develop-
ment of a necrotic core of soft unstable atheroma. Plaque inflam-
mation also triggers smooth muscle cell loss and the production of
matrix metalloproteinases (MMP) that weaken the fibrous cap,
predisposing it to plaque rupture [2,5]. The thick necrotic acellular
lipid core becomes increasingly hypoxic, stimulating angiogenesis,
with the formation of immaturemicrovessels prone to intra-plaque
haemorrhage (IPH) [6e8].
Similar to tuberculosis [9], calcification of atherosclerotic plaque
is thought to be a healing response to intense necrotic plaque
inflammation characterised by two distinct stages. In the latter
stage of macrocalcification, the healing process is complete and the
plaque stabilised [10e12]. By contrast, the earlier stage of micro-
calcification is a common feature of ruptured and unstable plaques
where healing is incomplete, inflammation remains active and the
fibrous cap weakened by the tiny calcific deposits [13e15].
Unstable plaques at risk of rupture, therefore, have certain
pathological features, including a large necrotic core, thin fibrous
cap, inflammation, hypoxia, haemorrhage and microcalcification.
By contrast, stable plaques at low risk of rupture have different
characteristics, including a thick fibrous cap and macroscopic
calcification. Advanced imaging now allows us to identify these
plaque characteristics in vivo and determine whether patients
predominantly have stable or unstable atheroma. Development of
hybrid molecular imaging allows us to measure disease activity in
the coronary arteries, directly. These developments hold promise in
altering how we define stable and unstable atherosclerosis and in
refining risk prediction beyond standard approaches. However, it
should be noted that the plaque characteristics and pathophysi-
ology underlying plaque erosion remain poorly understood, rep-
resenting an important limitation of this approach.
1.2. Atherosclerotic plaque imaging
Direct imaging of coronary atherosclerotic plaque is now
possible with CT calcium scoring (CACs) and coronary compu-
terised tomography angiography (CCTA). This has permitted more
accurate determination of coronary plaque burden, the presence of
both obstructive and non-obstructive disease and assessments of
plaque composition. Magnetic resonance (MR) whilst not as
advanced as CT can provide similar information without radiation
exposure, whilst novel PET approaches allow, for the first time,
assessment of coronary disease activity. These plaque-imaging
techniques are developing rapidly and, in the case of CT, starting
to enter routine clinical practice. They are discussed in greater
detail below and illustrated in Fig. 1.
1.3. Measures of plaque burden
Atherosclerotic plaque burden can be measured in different
vascular beds using multiple different modalities, including ultra-
sound, CT and MR. Regardless of the methodology, plaque burden
assessments provide powerful prognostic information, based upon
the rationale that the greater number of plaques, the more likely a
plaque is to rupture and cause an event.
CT calcium scoring is the best studied technique having been
incorporated in to clinical guidelines [16] and providing prognostic
information of incremental value to standard risk factor assess-
ments [17]. However, most patients with high CT calcium scores
will never suffer a clinical event. This may be because whilst CT
calcium provides a surrogate of global plaque volume, it actually
targets stable macrocalcific plaques, not the unstable plaques at
highest risk of rupture. Moreover, CT calcium scoring cannot
differentiate stable burnt-out disease from active unstableatheroma. Methods that can directly quantify unstable plaque and
assess disease activity are therefore required.1.4. Plaque morphological characteristics
Culprit plaques that have ruptured and caused an event have
certain histological characteristics. Indeed, many retrospective and
pathological studies have demonstrated the thin capped, fibro-fatty
atheromatous (TCFA) plaque as the cause for the majority of
myocardial infarctions and strokes [15,18e20]. Other recognised
features of potentially unstable plaques are microcalcification,
positive remodelling, inflammation and plaque haemorrhage [21],
each representing a potential imaging target to improve the iden-
tification of high risk patients. As with plaque burden, multiple
imaging modalities have been employed to better characterise
plaque morphology.
IVUS can assess plaque burden, positive remodelling and lipid
core. Moreover, virtual histology IVUS (VH-IVUS) allows direct
detection of the VH-IVUS TCFAs in the coronary vasculature
[22e24]. However, in the PROSPECT study of the 695 patients,
whilst 595 VH-IVUS TCFAs were identified, only 6 MIs were
observed over a 3-year period [25]. Comparable findings were re-
ported in the VIVA study [26], suggesting low predictive value of
these supposedly high-risk plaques [27,28]. We, therefore, prefer
the term unstable plaque characteristics.
The other main invasive assessment of unstable plaque is OCT.
This technique is particularly good at imaging the fibrous plaque,
with the ability to identify thin caps and both plaque rupture and
erosion [29,30]. Emerging OCT techniques offer assessment of
further unstable plaque characteristics including plaque macro-
phages and angiogenesis [31e33]. However, similar to VH-IVUS,
OCT-defined unstable plaques only rarely cause clinical events, so
that plaque directed therapies cannot be recommended [34].
Contrast coronary CT angiography (CCTA) offers major
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obstructive stenosis [35], providing improved diagnostic accuracy
and clinical outcomes in the assessment of patients presenting with
chest pain [36,37]. Second, it can inform about plaque morphology.
Unlike CACs, CCTA can identify non-calcified as well as calcified
plaque and can identify multiple unstable plaque characteristics.
These include low attenuation as a marker of necrotic core, positive
remodelling and spotty calcification (early macrocalcific deposits).
Multiple studies have demonstrated these features in culprit pla-
que post-myocardial infarction [38e41]. Moreover, Motoyama
recently demonstrated that patients with these unstable CT plaques
are at an elevated risk of subsequent myocardial infarction [42].
MR coronary angiography is a developing technology that re-
mains inferior to CCTA. However, MR can also identify unstable
coronary plaque characteristics, with T1 weighted imaging holding
particular promise. This approach makes use of the high T1 signal
associated with methaemoglobin, a key constituent of fresh
thrombus. On this basis, T1-weighted imaging can identify both
intraplaque haemorrhage and intraluminal thrombosis [43,44],
with increased signal localising to culprit carotid and coronary
plaques. Moreover, increased carotid and coronary signal identifies
patients at increased risk of subsequent stroke and MI, respectively
[45e47].
Several common themes appear to be emerging across these
vulnerable plaque studies. The first is that in prospective studies,
so-called vulnerable plaques in fact only rarely go on themselves to
cause clinical events. The majority will likely heal without conse-
quence whilst others may rupture sub-clinically without prompt-
ing myocardial infarction. Only a tiny minority will go on to cause a
clinical event. In these circumstances, invasive imaging and ther-
apies aimed at individual plaques do not make sense. However, the
CT and MRI studies discussed above suggest that unstable plaque
detection still holds promise in improving risk stratification at the
patient level and in directing the use of systemic therapies. Un-
stable plaques rarely exist in isolation and their identification can
highlight patients with an active disease process and an on-going
propensity to develop plaques with an unstable phenotypes [48].
Whilst most of the individual plaques will heal, with on-going
formation there is an increased probability of one such unstable
plaque eventually rupturing and causing an MI. Further work is
required to demonstrate the clinical utility of advanced coronary
plaque characterisation. In particular, it remains unclear whether
unstable plaque identification can improve patient risk stratifica-
tion over and above more simple assessments of plaque burden.
1.5. Imaging disease activity in atherosclerosis
The emergence of hybrid PET/CT scanners with advanced im-
aging capability has for the first time allowed assessment of
atherosclerotic disease activity. In principle, the activity of any
disease process can be assessed, however, in practice this is
dependent on the availability of PET tracers. To date, vascular PET
imaging has focused upon 18F-FDG: a marker of glucose utilisation
and a non-specific marker of inflammation that is limited to im-
aging of the carotid arteries, femoral arteries and aorta. However,
novel tracers are quickly emerging specific to multiple different
pathological processes. Moreover, technological developments
aimed at improving the (currently limited) spatial resolution of PET
now allow quantification of certain tracers in the coronary arteries.
Below, we discuss the current status of atherosclerotic plaque im-
aging using PET, SPECT, and a variety of different tracers.
1.6. Imaging inflammation with 18F-flurodeoxyglucose (FDG)
As described above, atherosclerosis is a chronic inflammatorydisease characterised by lipid deposition and macrophage infiltra-
tion. The recent CANTOS RCT of 10,061 patients with previous MI
and elevated CRP levels demonstrated, for the first time, that an
anti-inflammatory agent (150mg Canikinumab a monoclonal
antibody targeting Interleukin 1b) can reduce hard clinical end
points when compared to placebo. This trial therefore confirmed
the close relationship between inflammation and cardiovascular
events independent of lipid levels [49], and established inflam-
mation as a key target for therapeutic and novel molecular imaging
approaches.
18F-FDG PET has in fact been used to image inflammation for
over a decade, based upon the high glucose consumption of
vascular macrophages [50]. 18F-FDG competes physiologically with
glucose to enter the cell, where it becomes trapped and unable to
undergo further metabolism. FDG, therefore, accumulates in
metabolically active cells at a rate proportional to their glycolytic
activity [51].
The association between 18F-FDG activity and unstable
atherosclerotic plaque was first demonstrated by Rudd et al., who
observed increased uptake in symptomatic carotid plaques ipsi-
lateral to a recent stroke compared to the asymptomatic contra-
lateral plaque. Autoradiography of excised plaques confirmed
greatest uptake in macrophage rich plaques [52]. Here was the first
human evidence that active inflammation assessed by FDG PET
could accurately identify clinical plaque rupture. Other studies have
confirmed the close association between FDG uptake and macro-
phage burden on histology [53] as well as upregulated gene
expression of CD68 (a macrophage specific marker) [54]. Associa-
tion with other markers of plaque vulnerability have also been
established, including circulating MMP-1 levels [55], whilst an
elegant mechanistic study demonstrated that hypoxia potentiates
18F-FDG uptake by macrophages [56].
Recent studies have explored vascular 18F-FDG activity in sys-
temic inflammatory conditions, providing mechanism for the
increased cardiovascular event rates observed in these patients. In
particular patients with psoriasis have demonstrated increased
vascular 18F-FDG uptake beyond that explained by their cardio-
vascular risk factors [57], with similar results described for subjects
with both HIV and rheumatoid arthritis [58,59]. Moreover, Tahara
et al. reported increased carotid 18F-FDG uptake in patients with
metabolic syndrome [60], whilst Kim described increased activity
in diabetics and those with impaired glucose tolerance indepen-
dent of blood glucose [61].
Tawakol et al. recently elucidated the link between emotional
stress, increased vascular inflammation and cardiovascular events.
This elegant study embraced FDG's lack of specificity, indeed, it
harnessed it to investigate the relationship between processes
occurring in disparate organ system. The authors used resting 18F-
FDG uptake in the amygdala as a marker of emotional stress and
demonstrated an association with both FDG uptake in the bone
marrow (as a marker of hemopoietic activiation) and the vascula-
ture (as a marker of vascular inflammation). They also demon-
strated that increased 18F-FDG uptake in these tissues identified
patients with an increased risk of cardiovascular events, proposing
that stress causedmacrophagemobilisation from the bonemarrow,
increased vascular inflammation and clinical events [62]. Other
retrospective studies have also linked increased vascular 18F-FDG
activity to subsequent cardiovascular events. In a study of over 500
individuals devoid of a previous history of cardiovascular disease,
uptake in the ascending aorta strongly predicted the development
of cardiovascular disease independent of conventional risk factors
[63]. However, prospective outcome studies in non-biased patient
populations are now required to confirm the prognostic capability
of 18F-FDG PET.
18F-FDG PET is emerging as a novel method for assessing the
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sclerotic medication. The clinical efficacy of statins is well estab-
lished [64], it is, therefore, reassuring that statins consistently
reduce the arterial FDG signal in a dose dependent manner
[64e66]. Similarly, pioglitazone, which is associated with lower
rates of adverse cardiovascular outcomes in diabetics [67], has been
shown to attenuate vascular 18F-FDG uptake, further supporting
links between diabetes and vascular inflammation independent of
blood glucose levels [68,69].
By comparison, Dalcetrapib, a CETP inhibitor which increases
high density lipoprotein (HDL) levels, did not have any effect of
vascular 18F-FDG activity; an effect that was mirrored by a similar
inability to reduce adverse cardiovascular events [70,71]. Similarly,
the lipoprotein-associated phospholipase A2 (implicated in
atherosclerosis progression) inhibitor Rilapladib failed to reduce
both 18F-FDG uptake [72] and cardiovascular events in the STA-
BILITY trial of 15,000 patients [73]. Finally, the P38 mitogen acti-
vated protein kinase (MAP) failed to have a positive impact on
either the arterial 18F-FDG activity [74,75] or cardiovascular events
[76].
To summarise, large vessel FDG PET is a marker of vascular
inflammation, whose uptake acts a surrogate of plaquemacrophage
burden and is associated with conventional cardiovascular risk
factors and systemic inflammatory conditions. Importantly, FDG
uptake can be attenuated with medication, leading to its adoption
as an endpoint in trials assessing the anti-inflammatory effects of
novel therapies. With the development of increasingly expensive
atherosclerosis drugs, FDG may also prove useful for identifying
patients most likely to gain clinical benefit, although prospective
outcome trials are first required to assess whether it provides in-
dependent prognostic information.
Whilst FDG's lack of specificity has allowed investigators to
assess the links between vascular inflammation and both the brain
and bone marrow, it has limited the application of 18F-FDG PET to
the coronary arteries. Indeed, physiological uptake of 18F-FDG by
the myocardiummeans that coronary interpretation is challenging,
even despite meticulous dietary preparations [77]. The desire to
assess disease activity in the coronary arteries, the vascular bed
responsible for the majority of clinical events, has prompted
investigation of multiple novel tracers discussed below [78] (Fig. 2).Fig. 2. FDG performance in early phase clinical trials.
(A) CT on the left with corresponding PET image on the right demonstrating FDG uptake in
myocardium.1.7. Other PET tracers targeting inflammation
1.7.1. 68 Gallium-dotatate
Gallium 68 labelled DOTATATE targets the somatostatin recep-
tor subtype 2 (SSTR2) found on the surface of macrophages [79].
Pre-clinical studies have confirmed the superiority of 68Ga-
DOTATATE over FDG in terms of macrophage specificity in athero-
sclerotic inflammation [80] [81]. Early retrospective clinical studies
in cancer patients supported the pre-clinical findings and inter-
estingly found some discordance between FDG and DOTATATE ac-
tivity provoking further research [81e83]. Recently, a prospective
clinical study pitched DOTATATE versus FDG in the setting of
established aortic, carotid and coronary atherosclerosis. DOTATATE
demonstrated increased uptake in culprit coronary and carotid
arteries and outperformed FDG in discriminating between unstable
and stable coronary plaque as defined by CT. Histological validation
confirmed that DOTATATE uptake occurred in CD68-positive,
macrophage-rich carotid plaques. Specific binding to pro-
inflammatory M1 macrophages was demonstrated through exclu-
sive expression of the SSTR2 receptor [78]. These findings poise
DOTATATE PET as an exciting alternative to FDG, providing more
specific information about M1 macrophages in atherosclerotic
plaque that can be translated in the coronary arteries. Further
studies are on going in this area (Fig. 3).1.7.2. 18F-fluorocholine (18F-FCH)
Like many inflammatory tracers, 18F-FCH was first developed
for use in oncology. Via specific transport mechanisms, choline is
taken up into the cell, phosphorylated and metabolized to phos-
phatidylcholine and eventually incorporated into the cell mem-
brane. Increased choline uptake has been shown in tumor cells and
activated macrophages [84]. Its potential for human atherosclerotic
imaging was confirmed by ex vivo and in vivomouse model studies
of atherosclerosis where uptake was significantly higher in
atherosclerotic versus healthy aorta [85e87]. A strong association
between large vessel uptake and atherosclerotic changes in the
arterial wall has been demonstrated in a cohort of prostate cancer
patients with an apparent inverse relationship with calcification
[88]. This inverse relationship was confirmed in a larger study of 93
prostate cancer patients where only 6% of tracer uptake co-
localised with macrocalcification calcification and in all calcifiedculprit carotid plaque. (B) How FDG PET CT imaging can be applied to the aorta and
Fig. 3. Detection of coronary atherosclerotic inflammation by 68Ga DOTATATE.
The panels in the top row show the culprit lesion in the circumflex artery with corresponding angiogram (A), CT (B), and PET CT with 68GA DOTATATE (C) and FDG (D). The bottom
row of panels illustrates a bystander lesion in the proximal right coronary artery which is appears of moderate stenosis on angiography (A), appears non-calcified and positively
remodeled on CT angiography (F) and has a clear correlation of DOTATATE (G) and FDG (H) uptake [78].
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is now required.
1.7.3. 11C-PK11195
11C-PK11195 is a ligand of the 18-kDa translocator protein
(TSPO), which is highly expressed in human macrophages [90]. It
has been most widely used for neuroinflammatory imaging owing
to high microglial and low neuronal uptake and was first explored
in the cardiovascular system in patients with large vessel vasculitis
[91]. In atherosclerosis, 11C-PK11195 demonstrates increased up-
take in culprit carotid plaques following stroke, and a close asso-
ciation with inflammatory cell burden in carotid endarterectomy
specimens [92]. However, significant challenges with data inter-
pretation remain due to genotypic differences that govern the
metabolism of this tracer and have a profound effect on tracer ac-
tivity. Moreover, the short half-life (20min) of the tracer necessi-
tates an on-site cyclotron, limiting its availability and use. Other
next generation TSPO tracers are in development that seek to use
18F as a more convenient radiolabel and to avoid the genetic in-
fluences on metabolism.
1.8. Other novel atherosclerotic tracers
1.8.1. 18F-fluoromisonidazole (18F-FMISO)-hypoxia
FMISO targets hypoxia, an important process linked to athero-
sclerotic progression. As a plaque grows its core becomes pro-
gressively hypoxic promoting inflammatory cell infiltration and
further oxygen consumption, thereby further worsening hypoxic
conditions. Micro vessel formation ensues and is the necessarysubstrate for intraplaque haemorrhage; a key marker of plaque
vulnerability. In a rabbit model of aortic atherosclerosis, 18F-FMISO
was compared with 18F-FDG. In vivo and ex vivo PET imaging
demonstrated strong accumulation of 18F-FMISO accumulation in
areas of aortic atheroma, co-localising to regions of hypoxia
detected on immunohistochemistry with pimonidazole [93].
A recent study by Joshi et al. (Fig. 4) investigated FMISO PET in
patients with recent TIA or stroke (n¼ 16). FMISO uptake was
slightly higher in symptomatic plaques than contralateral lesions
(TBR 1.11± 0.07 vs. 1.05± 0.06; p< 0.05) and demonstrated a cor-
relation with FDG activity, suggesting once again that hypoxia
contributes to the inflammatory response and FDG uptake [78,94].
This tracer appears to hold future promise for atherosclerotic pla-
que imaging promoting greater understanding of the relationship
between hypoxia and inflammation.
1.8.2. 18F-fluciclatide-angiogenesis
18F-fluciclatide is a novel avb3 selective radiotracer and has
been investigated as a marker of angiogenesis following MI with
encouraging results. In a study of 37 patients, uptake was signifi-
cantly increased at sites of recent MI thereby acting as a biomarker
of cardiac repair and importantly predicting regions most likely to
recover contractile function [95]. Data regarding arterial uptake of
this tracer has not yet been published.
1.8.3. Annexin V (SPECT tracer) e apoptosis
99mTc labelled Annexin V has a high affinity for phosphati-
dylserine which is predominantly found on the plasma membrane
of apoptotic cells. It has primarily been used in oncology but has
Fig. 4. FMISO quantifies hypoxia in carotid plaques.
(A) Plaque in left internal carotid on contrast enhanced CT. Co-registered PET images with FDG (B) and FMISO (C) demonstrate a strong correlation of tracer uptake.
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atherosclerosis [96]. In a small study of those undergoing carotid
endarterectomy, uptake was shown to strongly correlate with high
risk plaque characteristics (macrophage infiltration and intraplaque
haemorrhage) suggesting a potential role for unstable plaque im-
aging [97].Fig. 5. CT characteristics of 18F-NaF uptake.
Coronary angiography in LAO caudal view showing severe proximal LAD lesion (A,
arrowed). Note co-localised PET uptake in (B, arrowed). CT allows assessment of plaque
density in (C) (<30 Hounsfield units). Hybrid PET CT in (D) shows co-localisation of 18-
fluoride uptake.1.8.4. 18F-sodium fluoride-microcalcification
The PET tracer 18F-sodium fluoride (18F-NaF) has been used for
many decades as a maker of increased bone metabolism. It works
via the exchange of 18F-NaF with hydroxyl groups on hydroxyap-
atite: a key structural component of both bone and vascular calci-
fication [98]. More recently, 18F-fluoride has been used to
investigate developing microcalcification in the vasculature,
emerging as a promising new PET radiotracer in the field of car-
diovascular medicine.
The intimal calcification observed in atherosclerosis is thought
to occur as a healing response to intense necrotic inflammation
within the plaque. At the outset, small crystals of hydroxyapatite
begin to coalesce into organised areas of microcalcification. The
natural continuation of this process is the formation of dense sheets
of macroscopic calcification that stabilize the plaque, effectively
walling off the necrotic core from the lumen. Whilst the end-stages
of macroscopic calcification impart stability, the early stages of
microcalcification are instead consistently associated with culprit
and unstable plaque phenotypes and an increased propensity to
rupture. In part, this may reflect the ongoing plaque inflammation
that is yet to heal and in part the increased mechanical stress
caused by microcalcific deposits in the fibrous cap that weaken its
tensile strength and predispose it to rupture [13].
Whilst CT is able to detect macroscopic calcification, including
early spotty calcification it is unable to resolve microcalcification.
However, this has now become possible with 18F-fluoride PET. Irkle
et al. demonstrated that 18F-fluoride binds preferentially to regions
of developing microcalcification in carotid atheroma, with little or
no binding to non-calcific tissue types [99]. Certainly, 18F-fluoride
PET provides different information to CT. In carotid atheroma,
coronary atheroma, aortic atheroma, aortic stenosis and AAA, 18F-
fluoride has consistently demonstrated a different pattern of up-
take to the macroscopic calcium observed on CT [98,100e102]. In
aortic stenosis, areas of increased 18F-fluoride activity predict
where novel deposits of macroscopic calcium will deposit,
providing excellent prediction of progression in CT calcium scoresof the valve [103,104]. Similar results have also been described in
atheroma, with a recent prospective study demonstrating the
ability of 18F-fluoride PET to predict progression in the CT calcium
score over 1 year in 34 patients [105]. This is potentially important
as fast calcium score progression is known to offer powerful
prognostic information of incremental value to single baseline
measurements [106].
Dweck et al. first demonstrated that coronary 18F-fluoride up-
take was associated with cardiovascular risk, demonstrating sig-
nificant associations between coronary arterial NaF uptake and
prior coronary events, angina status and Framingham risk scores
(p ¼ 0.016, p¼ 0.023 and p¼ 0.011, respectively) [96]. This was
supported by a study of 89 healthy adults, in whom 10-year risk
Fig. 6. A potential novel definition of stable and unstable coronary artery disease.
Note: this proposal would require extensive research and investigation before it could be recommended in routine clinical practice. Pending this current guideline, recommen-
dations for revascularsation and the prescription of optimal medical therapy should be followed.
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times higher amongst adults in the highest quartile of coronary
artery 18F-NaF uptake compared with those in the lowest (8.0 vs.
3.3%, p< 0.001) [107].
At the plaque level, 18F-fluoride localises to plaques with mul-
tiple unstable features, including inflammation, positive remodel-
ling, necrotic core and cell death as assessed by histology, VH-IVUS,
OCT and CT imaging [15,108]. Moreover, increased 18F-fluoride
uptake has been demonstrated in both culprit coronary and carotid
plaques after acute ischemic events. In a study of 40 patients with
recent MI, increased uptake localised to the culprit plaque in 93% of
patients. Similar findings were observed in a small MR/PET study
[109], whilst in the carotid arteries increased 18F-fluoride uptake
was observed in the culprit carotid plaque of patients with recent
stroke/TIA) versus controls [110]. This finding was confirmed in a
case control study by Vesey et al. (n¼ 26), who also demonstrated
increased 18F-fluoride uptake in ipsilateral versus contralateral
carotid plaques and that once again was associated with unstable
plaque features, plaque burden and cardiovascular risk factors [111]
(Fig. 5).
Together, this data suggests that 18F-fluoride allows detection of
both unstable and culprit plaque with increased coronary uptake
being observed in patients with increased disease activity and at
increased cardiovascular risk. Whether it provides incremental
prospective prediction of cardiovascular events compared to con-
ventional risk scores and CT imaging will be investigated in the
prospective, multicenter PREFFIR trial (NCT02278211). Unlike FDG,
drug trials evaluating the effects of cardiovascular medicines on
18F-fluoride uptake are lacking, although the on going SALTIRE 2
study is assessing the effects of bisphosphonates and Denosumab
on vascular calcification activity in aortic stenosis (NCT 02132026).
It should provide proof of concept as to whether the vascular 18F-
fluoride signal is modifiable.
1.9. A novel definition of stable and unstable coronary artery
disease
Patients with coronary atherosclerosis have traditionally been
divided into two groups depending on their symptom pattern.
Patients with stable coronary artery disease are classically either
asymptomatic or experience predictable exertional angina
[112,113]. The assumption has been that, like their symptoms, these
patients have stable inactive atherosclerosis at low risk of rupture.
By contrast, patients with unstable coronary artery disease describe
rapid and unpredictable symptom escalation that reflects a highly
active and unstable underlying disease process. Modern imaging
technology now allows us to examine coronary plaque character-
istics and disease activity directly. These indicate that some
apparently stable patients in fact also have an active underlying
disease process characterised by the dynamic formation and reso-
lution of multiple unstable coronary plaques. Early data suggest
that these clinically stable but biologically active patients may be at
increased cardiovascular risk and therefore may benefit from
aggressive medical therapy and potentially even revascularisation
[107]. Equally, patients with disease that is both clinically and
biologically stable could have therapy tailored back potentially
avoiding expensive and intrusive revascularisation strategies.
Further studies are required to investigate this hypothesis and to
investigate whether it is cost-effective before adoption in to clinical
practice (Fig. 6).
2. Conclusion
Modern non-invasive imaging using CT, MR and PET now allows
identification of unstable characteristics and the directmeasurement of disease activity in the coronary arteries and large
vessels. This advance appears set to improve our pathological un-
derstanding of atherosclerosis and has the potential to redefine our
understanding of what stable and unstable atherosclerosis truly
represents. Indeed, ultimately, we may be able to track disease
activity and the transition between stable and unstable disease
states with time and in response to therapy. Further work is now
required to validate these early findings and to investigate whether
these novel imaging approaches provide incremental prognostic
information.
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